Hand Rejuvenation: Filler, Fat, Lasers and Peels for Aging Hands, Compared by Evidence
Start with our pillar guide: Dermal Fillers for Ozempic Face: What the Evidence Shows (and Doesn't), or browse all Aesthetic Treatments articles.
Hand rejuvenation treats two separate problems: lost volume, which exposes veins and tendons, and sun damage, which causes spots and rough texture. Calcium hydroxylapatite filler and Restylane Lyft, a hyaluronic acid filler, are FDA-approved for the hands, while lasers, intense pulsed light and peels target the surface. Put plainly, the evidence is weak and often industry-tied: most of it is review-level or expert consensus, several key papers have authors paid by product makers, and none of the abstracts we reviewed reports a randomized trial with hand-specific results, though a cited review's reference list includes randomized calcium hydroxylapatite hand trials we didn't assess.
Evidence: Limited.
Key takeaways
- A 2015 review by Riyaz and Ozog separates hand aging into surface photoaging and soft tissue atrophy, and matches different treatments to each (Riyaz and Ozog, 2015).
- A 2024 systematic review states that the hands are the only FDA-approved body indication for calcium hydroxylapatite, and that diluted use has yet to be supported by randomized trials (Galadari and Guida, 2024).
- A 2025 consensus paper whose 19 authors all have Galderma ties says data support a "potential benefit" for poly-L-lactic acid in hands, based largely on observational studies and case series (Haddad et al., 2025).
- A 2023 systematic review puts fat graft survival at 25% to 80% across lipofilling in general, not in hands alone (Debuc et al., 2023).
- A 2023 case series of 50 patients reported an 81.6% average improvement, but it pooled the face, neck, décolletage and hands (Massidda, 2023).
What is hand rejuvenation, and which problem are you treating?
Hand rejuvenation is a group of treatments for two different problems: lost volume under the skin and sun damage on its surface. Most treatments in our sources target one or the other, though a fat grafting technique article reports long-term changes in skin texture and appearance, with visible superficial veins disappearing (Rohrich and Abraham, 2023).
Riyaz and Ozog's 2015 review says hands age through natural processes and chronic UV exposure (Riyaz and Ozog, 2015). Photoaging, or skin aging from UV light, shows up as pigment changes, rough texture and wrinkles. Soft tissue atrophy means the padding under the skin thins, leaving bones, tendons and veins easier to see. The review reports "favorable outcomes for most patients," but its abstract gives no figures, and funding isn't reported there.
Facial volume is a separate topic, covered in our pillar guide to dermal fillers for Ozempic face. The table below covers the hand options in our sources. "Not stated" means our sources don't give an FDA status, not that the option is unapproved.
| Option | Problem treated | FDA status for hands | Evidence grade | Company ties |
|---|---|---|---|---|
| CaHA filler (Radiesse) | Volume loss | Approved (Galadari) | Limited | Not reported in abstract |
| Diluted or hyperdiluted CaHA | Laxity, skin quality | Consensus calls diluted use off-label in the face and body; hands not named (Goldie) | Early / preliminary | Consensus has no conflict statement in the record; case series author reports none |
| PLLA (Sculptra) | Volume loss, skin appearance | PLLA: facial approval stated; no hand approval stated (Haddad) | Early / preliminary | All 19 consensus authors Galderma-tied (4 employees); review author a Sinclair consultant |
| Hyaluronic acid filler | Volume loss | FDA-approved for the back of the hand (Restylane Lyft; FDA premarket approval P040024/S099, May 18, 2018) | Limited | Not reported in abstract |
| Your own fat | Volume loss | Not stated | Limited | One review reports none; one technique author has instrument royalties |
| Polycaprolactone filler (Ellansé) | Volume loss | Not stated | Early / preliminary | Sinclair consultants and advisor, some of whom also disclose IBSA or Anteis ties; another author a Teoxane tie |
| Polynucleotide injections | Skin revitalization | Not stated | Early / preliminary | Board received industry grants; Mastelli paid support costs |
| Chemical peels | Sun damage | Not stated | Limited | No relevant ties declared |
| Lasers, IPL, photodynamic therapy | Sun damage | Not stated | Limited | Not reported in abstract |
| Skin excision | Excess skin | Not stated | Early / preliminary | Not reported in abstract |
Evidence: Limited.
Should you choose filler or fat for hand rejuvenation?
No head-to-head trial in the abstracts we reviewed shows that filler or fat is better. CaHA has a stated FDA approval for hands, while fat has favorable review-level support but unpredictable survival.
The choice between Sculptra and Radiesse has its own page: Sculptra vs Radiesse. Here, we focus on approval status and hand evidence.
Calcium hydroxylapatite
CaHA is a filler made of mineral particles in a gel. A 2024 systematic review states that "the only FDA-approved indication on the body is treating the hands" (Galadari and Guida, 2024). The number of included studies isn't given in the abstract, and neither is funding.
Diluted use is different. A 2018 consensus paper calls its guidelines "preliminary" and describes a "novel off-label use" for collagen stimulation (Goldie et al., 2018). Its abstract lists the face, neck, décolletage, arms, abdomen, legs and buttocks for laxity, but it doesn't name the hands. The first author is listed at European Medical Aesthetics Ltd, a London company; the record shows no link to a product maker and no conflict statement.
The Massidda case series used diluted and hyperdiluted Radiesse in 50 patients, with no control group and duration not reported (Massidda, 2023). The 81.6% average improvement covers all treated sites, so it can't be read as a hand result. The author reports no conflicts.
Poly-L-lactic acid
PLLA is an injectable collagen stimulator. The consensus abstract says it has been approved for facial aesthetic uses since 2009 in the US (Haddad et al., 2025); it doesn't use the word off-label, but hands fall outside that facial approval. That Level IV consensus says the body evidence consists largely of prospective observational analyses and case series. Four authors are Galderma employees, and all 15 others declare Galderma speaker, trainer, consultant or investigator roles; several also declare ties to Merz or Allergan, and individual authors to IBSA, Revance and others. PubMed tags it as non-US-government support, without naming a funder.
A separate 2022 review calls the published body data "still limited" and includes hands among the areas covered (Christen, 2022). Its sole author consults for Sinclair Pharma.
Your own fat
A 2020 review says fat grafting "has been demonstrated to be a safe and effective method of hand rejuvenation," and it cites high patient satisfaction without figures in the abstract (Conlon et al., 2020). None of its authors has a financial interest in the products mentioned.
The main uncertainty is how much fat survives. A 2023 systematic review describes graft survival as "unpredictable and low," ranging from 25% to 80% across uses such as breast reconstruction and facial and hand rejuvenation (Debuc et al., 2023). PubMed tags it as non-US-government support; the funder isn't named in the abstract. Its enrichment strategies, including added stem cells, draw on both preclinical and clinical work and aren't established for hands.
A 2023 technique article argues that fat grafting should be offered as "the standard of care" for moderately to severely aged hands (Rohrich and Abraham, 2023). That is expert opinion, and the abstract gives no result numbers. Dr. Rohrich receives instrument royalties from Eriem Surgical.
| Feature | Injectable filler | Your own fat |
|---|---|---|
| Material | Manufactured product such as CaHA, PLLA or hyaluronic acid | Autologous fat, meaning fat from your own body |
| FDA status for hands | CaHA and Restylane Lyft approved; PLLA: facial approval stated; no hand approval stated | Not stated in our sources |
| Strongest supportive claim | CaHA has an approved hand indication | A 2020 review calls it safe and effective |
| Biggest unknown | No hand-specific result numbers in the abstracts we reviewed | Graft survival of 25% to 80% in general lipofilling |
| Head-to-head trial in the abstracts we reviewed | None | None |
Bottom line: The abstracts we reviewed can't show that either option is better. They mainly show differences in approval status and known unknowns.
Newer injectables
Two other products have expert guidance rather than hand results in the abstracts we reviewed. A group whose authors are mostly Sinclair consultants, some of whom also disclose IBSA or Anteis ties, and another author a Teoxane tie, wrote recommendations for polycaprolactone, a collagen-stimulating filler, including hands (de Melo et al., 2017). An 8-expert panel reached more than 80% consensus on polynucleotide injections, including hands (Cavallini et al., 2021). Its board members received industry grants, past sponsors of board members included patent holder Mastelli, and Mastelli supported logistics and publication costs.
A 2025 review with no declared conflicts also covers fillers for the neck, chest and hands, but its abstract gives no result numbers (El Hawa et al., 2025).
| Galadari and Guida, Int J Dermatol, 2024 | Not reported | Not reported | CaHA, body use | Hands are the only FDA-approved body indication; diluted use lacks randomized trial support |
| Goldie et al., Dermatol Surg, 2018 | Expert panel; size not reported | Not applicable | Diluted and hyperdiluted CaHA | Preliminary off-label guidelines; injection-related adverse events listed |
| Haddad et al., Aesthetic Plast Surg, 2025 | Expert panel | Not applicable | PLLA, body use | Potential benefit for hands; evidence largely observational |
| Conlon et al., Semin Plast Surg, 2020 | Not reported | Not reported | Fat grafting to the hands | Described as safe and effective; high satisfaction without figures in abstract |
| Debuc et al., Stem Cell Rev Rep, 2023 | Not reported | Not reported | Lipofilling across body sites | Graft survival ranges from 25% to 80% |
| Massidda, Clin Cosmet Investig Dermatol, 2023 | 50 | Not reported | Diluted and hyperdiluted Radiesse; ratios varied | 81.6% average improvement across mixed sites; no significant adverse effects |
Galadari and Guida, Int J Dermatol, 2024
Result: Hands are the only FDA-approved body indication; diluted use lacks randomized trial support
Systematic review. Funding not reported in abstract. Evidence: Limited.
Goldie et al., Dermatol Surg, 2018
Result: Preliminary off-label guidelines; injection-related adverse events listed
Global consensus. First author at European Medical Aesthetics Ltd. Evidence: Early / preliminary.
Haddad et al., Aesthetic Plast Surg, 2025
Result: Potential benefit for hands; evidence largely observational
Level IV consensus. All 19 authors have Galderma ties, including 4 employees. Evidence: Early / preliminary.
Conlon et al., Semin Plast Surg, 2020
Result: Described as safe and effective; high satisfaction without figures in abstract
Review. No financial interests declared. Evidence: Limited.
Debuc et al., Stem Cell Rev Rep, 2023
Result: Graft survival ranges from 25% to 80%
Systematic review, not hand-specific. PubMed tags it as non-US-government support; funder not named. Evidence: Limited.
Massidda, Clin Cosmet Investig Dermatol, 2023
Result: 81.6% average improvement across mixed sites; no significant adverse effects
Uncontrolled case series with no separate hand result in the abstract. Author reports no conflicts. Evidence: Early / preliminary.
None of these sources reports a randomized trial or a hand-specific efficacy number in its abstract.
Evidence: Limited for CaHA and fat; Early / preliminary for other injectables.
Which aging hands treatment works for sun damage: lasers, IPL or peels?
Reviews list lasers, intense pulsed light (IPL) and chemical peels for sun-damaged hands, but the abstracts we reviewed give no hand-specific result figures. These are surface treatments, so they aren't described as replacing lost volume.
Riyaz and Ozog list chemical peels, Q-switched lasers, resurfacing lasers, IPL and photodynamic therapy for photoaging (Riyaz and Ozog, 2015). Q-switched lasers deliver very short pulses of light, while photodynamic therapy uses light to activate a skin-applied drug. The abstract doesn't compare these options or give improvement rates.
A 2023 StatPearls chapter says a chemical peel works through controlled skin damage that prompts regeneration, and it "can restore a youthful appearance of the aging face, neck, and hands" (Samargandy and Raggio, 2023). The authors declare no relevant financial relationships. If you have a peel, see our guide to chemical peel aftercare.
A 2004 multistage protocol paired topical therapies and IPL for age spots and leathery texture with fat injections, then removed excess skin through a small incision (Weiss and Carraway, 2004). Its abstract reports no patient numbers or outcomes. Facial dark spots are covered in our guide to vitamin C for hyperpigmentation. Evidence: Limited.
Can creams help aging hands?
We found no study that measures a cream on aging hands, so we can't say that any cream reverses hand aging. The closest source only mentions topical therapies as one stage of a clinic protocol.
That 2004 protocol doesn't name the topical products or report their results (Weiss and Carraway, 2004). Because chronic UV exposure contributes to hand aging (Riyaz and Ozog, 2015), sun protection is standard clinic advice. No study in our sources tests it on hands.
The same gap applies to retinoids. Our tretinoin guide covers wrinkle trials as general background, but nothing in our sources tests tretinoin on hands. Evidence: Limited; no hand-specific topical studies in our sources.
What are the risks of hand rejuvenation?
For diluted calcium hydroxylapatite in the face and body, a consensus paper lists adverse events including bruising, swelling, mild pain and firmness (Goldie et al., 2018). The abstracts we reviewed give no rates for serious complications in hands, so "well tolerated" doesn't mean the risk is known.
The Goldie consensus says adverse events with diluted CaHA are related to injection and include bruising, swelling, mild pain and induration, meaning firmness under the skin (Goldie et al., 2018). It adds that too-superficial injections of less diluted CaHA can lead to more adverse events in thinner and darker skin. Those findings cover the face and body, not hands alone.
Other safety statements are general. The Massidda case series reported no significant adverse effects among 50 patients treated at mixed sites (Massidda, 2023). The Christen review says collagen stimulators cause mainly minor adverse events (Christen, 2022). Neither abstract gives a hand-specific complication rate.
None of the abstracts in our sources gives a rate for vascular injury or nodules in hands. Riyaz and Ozog refer to "known complications" without listing them (Riyaz and Ozog, 2015). Choosing an experienced injector is clinic convention, and no study in our sources tests how much it changes outcomes. Evidence: Limited.
How long does hand rejuvenation last?
The abstracts we reviewed don't say. They give no hand-specific figures on how long any treatment lasts, although cited reference lists include a 12-month randomized calcium hydroxylapatite hand trial and a 12-year single-surgeon fat grafting report and other hand reports whose follow-up we didn't assess.
Several abstracts use reassuring language without giving hand-specific timelines. The Rohrich article refers to "long-term results" (Rohrich and Abraham, 2023), and the Galderma-tied Haddad consensus says body improvements can be "sustained over time" (Haddad et al., 2025). The Christen review describes collagen stimulators as long-lasting (Christen, 2022).
The El Hawa review says it details filler durability, but its abstract gives no figures (El Hawa et al., 2025). The 25% to 80% graft survival range gives another reason for caution with fat, though it isn't a hand-specific measure (Debuc et al., 2023). Evidence: Limited; no hand-specific duration data in the abstracts we reviewed.
What should you ask before booking hand rejuvenation?
Ask which problem the treatment targets, what exact product will be used, and how complications are handled. This checklist is clinic convention rather than a study-tested tool, but it covers the gaps in the evidence above.
- Which problem are you treating? Volume loss and sun damage call for different types of treatment (Riyaz and Ozog, 2015).
- What is the exact product? Ask for the brand name and whether it will be diluted.
- Is this use FDA-approved for hands? CaHA and Restylane Lyft (FDA premarket approval P040024/S099, May 18, 2018) have hand approvals; a consensus calls diluted CaHA off-label in the face and body without naming hands, and for PLLA a facial approval is stated and no hand approval is stated (Goldie et al., 2018; Haddad et al., 2025).
- How many sessions do you expect? Ask what happens if you need more than planned.
- What results have you followed over time? The abstracts we reviewed give no hand-specific durability data, so ask about the clinician's own follow-up.
- What is your complications plan? Ask who you call, what they treat and how quickly you'd be seen.
- How does your plan account for my skin? Thinner and darker skin were specifically flagged for superficial injections of less diluted CaHA (Goldie et al., 2018).
Evidence: Limited; the checklist itself is clinic convention.
Where the evidence stops
- No randomized trials in the abstracts we reviewed. None reports one, though the Galadari review's reference list includes randomized calcium hydroxylapatite hand trials (one with 12 months of follow-up) that we didn't assess.
- No hand-specific efficacy numbers in the abstracts we reviewed. The 81.6% figure pools several body areas, and the 25% to 80% survival range covers lipofilling in general.
- No head-to-head trials in the abstracts we reviewed. One technique article argues fat has benefits over fillers, without trial data in its abstract.
- No hand durability data in the abstracts. The abstracts we reviewed give no figures for how long any option lasts in hands; cited reference lists include a 12-year single-surgeon fat grafting report and other hand reports whose follow-up we didn't assess.
- No serious-complication rates. The abstracts we reviewed give no rates for vascular events or nodules in hands.
- No topical data. No source measures a cream on aging hands.
- Heavy industry involvement. Much of the injectable literature comes from authors with company ties.
FAQ
What is hand rejuvenation?
Hand rejuvenation is a group of treatments for aging hands. Fillers or your own fat address lost volume, while peels, lasers and intense pulsed light address sun damage such as spots and rough texture.
Is filler in the hands FDA-approved?
Calcium hydroxylapatite is approved for the hands, which a 2024 systematic review names as its only FDA-approved indication on the body. Restylane Lyft, a hyaluronic acid filler, was FDA-approved in 2018 for volume loss on the back of the hand (FDA premarket approval P040024/S099, May 18, 2018). A consensus paper calls diluted calcium hydroxylapatite off-label in the face and body without naming hands, and for poly-L-lactic acid, a facial approval is stated and no hand approval is stated. Ask your clinician about the exact product.
Is fat grafting better than filler for hands?
No head-to-head trial in the abstracts we reviewed answers this. A review calls fat grafting safe and effective for hands, but a separate systematic review reports graft survival of 25% to 80% across lipofilling in general, not in hands alone.
What are the side effects of hand filler?
A consensus paper on diluted calcium hydroxylapatite in the face and body lists bruising, swelling, mild pain and induration, meaning firmness under the skin. Too-superficial injections of less diluted product can cause more adverse events in thinner and darker skin. The abstracts we reviewed give no rates for serious complications, so ask your injector about them.
Can lasers or peels fix age spots on hands?
Reviews list Q-switched lasers, resurfacing lasers, intense pulsed light, photodynamic therapy and chemical peels as options for sun-damaged hands. The abstracts we reviewed give no hand-specific result figures, so they can't show how much spots will fade.
Does Sculptra work on hands?
A 2025 consensus paper says current data support a potential benefit of poly-L-lactic acid for hands, but the evidence is largely observational. All 19 authors have Galderma ties, including 4 employees, and the abstract states PLLA's US approval for facial use and mentions no hand approval.
How long does hand rejuvenation last?
The abstracts we reviewed give no hand-specific data on how long results last. Some papers describe long-term or sustained results, but their abstracts give no duration for hands. Ask your provider what follow-up they have seen and how they handle touch-ups.
Can creams reverse aging hands?
We found no studies measuring creams on aging hands. A 2004 protocol includes unnamed topical therapies but reports no results. Sun protection is standard clinic advice, not a tested hand treatment in our sources.
References
- Riyaz FR, Ozog D. Hand rejuvenation. Semin Cutan Med Surg. 2015. Review; n and funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/26566571/
- Galadari H, Guida S. A systematic review of Radiesse® (calcium hydroxylapatite): evidence and recommendations for the body. Int J Dermatol. 2024. Systematic review; number of studies and funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/38390986/
- Goldie K, et al. Global Consensus Guidelines for the Injection of Diluted and Hyperdiluted Calcium Hydroxylapatite for Skin Tightening. Dermatol Surg. 2018. Expert consensus; panel size not reported in abstract; first author at European Medical Aesthetics Ltd; erratum published; not assessed. https://pubmed.ncbi.nlm.nih.gov/30358631/
- Haddad A, et al. Injectable Poly-L-Lactic Acid for Body Aesthetic Treatments: An International Consensus on Evidence Assessment and Practical Recommendations. Aesthetic Plast Surg. 2025. Level IV expert consensus; all 19 authors have Galderma ties (4 employees), several also Merz or Allergan; PubMed tags non-US-government support, funder not named. https://pubmed.ncbi.nlm.nih.gov/39592491/
- Christen MO. Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA). Clin Cosmet Investig Dermatol. 2022. Review; author is a consultant for Sinclair Pharma. https://pubmed.ncbi.nlm.nih.gov/35761856/
- Conlon CJ, et al. Fat Grafting for Hand Rejuvenation. Semin Plast Surg. 2020. Review; no financial interests in products mentioned. https://pubmed.ncbi.nlm.nih.gov/32071579/
- Debuc B, et al. Improving Autologous Fat Grafting in Regenerative Surgery through Stem Cell-Assisted Lipotransfer. Stem Cell Rev Rep. 2023. Systematic review, not hand-specific; PubMed tags it as non-US-government support, funder not named in abstract. https://pubmed.ncbi.nlm.nih.gov/37261667/
- Rohrich RJ, Abraham JT. Hand Rejuvenation with Fat Grafting. Plast Reconstr Surg. 2023. Technique article; n not reported; Dr. Rohrich receives instrument royalties from Eriem Surgical and book royalties from Thieme; no research funds received. https://pubmed.ncbi.nlm.nih.gov/36729928/
- Samargandy S, Raggio BS. Chemical Peels for Skin Resurfacing. StatPearls [Internet]. StatPearls Publishing; 2023. Book chapter review; authors declare no relevant financial relationships. https://pubmed.ncbi.nlm.nih.gov/31613532/
- Massidda E. Starting Point for Protocols on the Use of Hyperdiluted Calcium Hydroxylapatite (Radiesse(®)) for Optimizing Age-Related Biostimulation and Rejuvenation of Face, Neck, Décolletage and Hands: A Case Series Report. Clin Cosmet Investig Dermatol. 2023. Uncontrolled case series, n=50, mixed sites, duration not reported; author reports no conflicts. https://pubmed.ncbi.nlm.nih.gov/38050476/
- Weiss DD, Carraway JH. Hand rejuvenation. Aesthet Surg J. 2004. Multistage protocol description; n and funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/19336212/
- de Melo F, et al. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellansé(®)). Clin Cosmet Investig Dermatol. 2017. Expert recommendations; 7 authors are Sinclair consultants, 1 is a Sinclair medical advisor; some of the consultants also disclose IBSA or Anteis ties, and another author a Teoxane tie. https://pubmed.ncbi.nlm.nih.gov/29184426/
- Cavallini M, et al. Consensus report on the use of PN-HPT™ (polynucleotides highly purified technology) in aesthetic medicine. J Cosmet Dermatol. 2021. Expert consensus, 8 experts; board received industry grants; Mastelli was a past sponsor of board members and supported logistic and publication costs. https://pubmed.ncbi.nlm.nih.gov/32799391/
- El Hawa M, et al. Non-Facial Skin Rejuvenation of the Neck, Chest, and Hands. Part One: Using Injections. J Cosmet Dermatol. 2025. Literature review; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/39548357/
- FDA premarket approval P040024/S099, May 18, 2018 (Restylane Lyft; injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over 21).
Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Hand fillers and fat grafting are medical procedures; choose a qualified, experienced clinician and ask about complications before booking.